Posted by Michael Wonder on 20 Jun 2019
Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions
19 June 2019 - As politicians and policymakers debate effective ways to rein in rising health care costs, biosimilars represent an obvious solution for saving billions of dollars a year.
These products offer the same safety and effectiveness as the reference biologics they are designed to match. So why aren’t they being embraced by patients, physicians, and payers?
Blame that in part on misinformation about these products — some of it coming from the pharmaceutical industry — and the lack of market preparation to support the uptake of biosimilars in the U.S.
